Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options

1

Dupixent (dupilumab) is now approved for pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) in the US.
2

The approval is based on the Phase 3 LIBERTY-CUPID clinical program, demonstrating efficacy in reducing itch severity and urticaria activity.
3

Dupilumab showed higher rates of well-controlled disease and complete response compared to standard antihistamine therapy.
4

Injection site reactions were the most common adverse events, but no new safety concerns were identified in the pediatric population.
5

Dupilumab is the first biologic therapy approved in the US for young children with uncontrolled CSU, expanding treatment options.

1